Levamlodipine

Generic Name: Levamlodipine

Brand Names: Conjupri

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₅ClN_₂O_₅

CAS Number: 103129-82-4

Unique Ingredient Identifier: 0P6NLP6806

Background: Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of amlodipine, an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity.

Levamlodipine was granted FDA approval on 19 December 2019.

Indication: Levamlodipine is indicated alone or in combination to treat hypertension in adults and children.

Associated Conditions: Hypertension

Clinical Trials

A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients

Phase 3

Not yet recruiting

Conditions: Mild-to-moderate Essential Hypertension

Interventions: Drug: SYH9056
Drug: Valsartan
Drug: Levamlodipine
Drug: Levamlodipine placebo
Drug: SYH9056 placebo
Drug: valsartan placebo

First Posted Date: 2025-01-13

Last Posted Date: 2025-01-13

Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Target Recruit Count: 606

Registration Number: NCT06771245

Efficacy and Safety of Mexartan Potassium Tablets (AZL-M) and Calcium Channel Blockers (CCB) in the Treatment of Adults With Essential Hypertension in Chinese Population: a National Multicenter, Prospective, Observational Study

Recruiting

Conditions: Essential Hypertension

Interventions: Drug: Azilsartan Medoxomil Potassium Tablet
Drug: Nifedipine Sustained -release Tablets
Drug: Levoamlodipine Maleate Table

First Posted Date: 2023-07-17

Last Posted Date: 2024-04-01

Lead Sponsor: Hasten Biopharmaceutical Co., Ltd.

Target Recruit Count: 1215

Registration Number: NCT05947448

Locations: 🇨🇳
Junbo Ge, Shanghai, Shanghai, China

Anti Inflammatory Treatment of Hypertension

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: Amlodipine
Drug: Levamlodipine

First Posted Date: 2021-02-05

Last Posted Date: 2021-02-05

Lead Sponsor: Afﬁliated Hospital of North Sichuan Medical College

Target Recruit Count: 200

Registration Number: NCT04740840

Comparing Safety and Efficacy of Amlodipine Verses S Amlodipine in Patients With Essential Hypertension

Conditions: Essential Hypertension

Interventions: Drug: S-amlodipine 2.5mg
Drug: Amlodipine 5mg

First Posted Date: 2020-09-18

Last Posted Date: 2020-11-12

Lead Sponsor: Ahn-Gook Pharmaceuticals Co.,Ltd

Target Recruit Count: 80

Registration Number: NCT04554303

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

Bioequivalence of Levamlodipine Besylate Tablets in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Levamlodipine 5 mg
Drug: Amlodipine 10 mg

First Posted Date: 2020-06-02

Last Posted Date: 2020-06-05

Lead Sponsor: The Affiliated Hospital of Qingdao University

Target Recruit Count: 48

Registration Number: NCT04411875

Locations: 🇨🇳
Phase Ⅰ Clinical Research Center, Qingdao, Shandong, China

Efficacy and Safety of Leningrado Association in the Treatment of Hypertension

Phase 3

Withdrawn

Conditions: Arterial Hypertension

Interventions: Drug: LENINGRADO association
Drug: Indapamide SR 1.5 MG
Drug: Levamlodipine 2.5/ 5 mg
Other: Leningrado association Placebo
Other: Levamlodipine placebo
Other: Indapamide SR Placebo

First Posted Date: 2019-01-23

Last Posted Date: 2022-07-27

Lead Sponsor: EMS

Registration Number: NCT03814109

Bioavailability of 5 mg of Levamlodipine Maleate Tablets Versus 10 mg of Amlodipine Besylate Tablet in Healthy Subjects

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Levamlodipine, Amlodipine
Drug: Amlodipine, Levamlodipine

First Posted Date: 2018-09-05

Last Posted Date: 2021-09-16

Lead Sponsor: Conjupro Biotherapeutics, Inc.

Target Recruit Count: 36

Registration Number: NCT03657550

Locations: 🇺🇸
Collaborative Neuroscience Network, LLC, Long Beach, California, United States

S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension

Phase 4

Conditions: Essential Hypertension

Interventions: Drug: S-amlodipine 2.5mg + Telmisartan 40mg
Drug: S-amlodipine 2.5mg + Chlorthalidone 25mg

First Posted Date: 2017-07-21

Last Posted Date: 2017-07-21

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 170

Registration Number: NCT03226340

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
🇰🇷
Korea Univ. Guro Hospital, Seoul, Guro, Korea, Republic of
🇰🇷
Ajou Univ. Medical Center, Suwon-si, Yeong-tong, Korea, Republic of

and more 6 locations